Results for Announcement to the Market
For the Six Months Ended 30 June 2010
(Previous corresponding period: Six months ended 30 June 2009)

Revenue and Net Loss

		Percentage Change		**Amount**
		%		**US$'000**
Revenue from ordinary activities	Up	38	To	6,168
Loss from ordinary activities after tax attributable to members	Down	-35	To	4,054
Net loss for the period attributable to members	Down	-35	To	4,054

Revenue

Revenue surpassed the preceding year by US$1,702,000 as the Group regained its market share in Vietnam and improved its performance in Australia. The increase in revenue was however, partially offset by inactivity in India during the current financial period.

Net Loss

There was a reduction in net loss as compared with the corresponding period, primarily attributable to :

- Better revenue performance in all segments except for India, coupled with a 5% increase in gross profit margin ; and
- Gain on disposal of investment property in India.

Dividend

The Company does not propose to pay dividends for the six months ended 30 June 2010.

SCIGEN LTD AND ITS SUBSIDIARIES

REPORT OF THE DIRECTORS

The directors present their report together with the condensed consolidated interim financial statements for the six-month period ended 30 June, 2010.

1 DIRECTORS

The directors of the Company in office at the date of this report are:

Mr. Ryszard Krysztof Krauze
Mr. Slawomir Ziegert
Mr. Martin Cooper
Ms. Jenny Low
Mr. Kenneth Gross
Mr. Adam Wilczega
Ms. Joanna Szymańska-Bulska
Mr. Marcin Dukaczewski
Mr. Adam Polonek
Dr. Marian Gorecki
Mr. Mateusz Patryk Kosecki
Mr. Amol Jashvant Shah

2 REVIEW OF OPERATIONS

A summary of consolidated revenues and results for the six months by significant geographical segments is set out below:

	Segment Revenue		**Segment Results**	
	30 June, 2010 US$'000	30 June, 2009 US$'000	30 June, 2010 US$'000	30 June, 2009 US$'000
Singapore	909	706	(15)	596
Australia	2,202	1,660	511	(511)
India	-	954	(304)	104
Korea	711	610	(78)	(52)
Thailand	823	776	111	98
Israel	50	-	(2,251)	(63)
Vietnam	1,682	-	284	(16)
Philippines	653	466	112	12
China	-	-	(336)	(117)
Others	47	-	13	101
Eliminations	(909)	(706)	-	-
	6,168	4,466	(1,953)	152
Unallocated revenue less unallocated expenses			(2,195)	(6,429)
Loss from ordinary activities before income tax			(4,148)	(6,277)
Income tax expense			(71)	(26)
Loss for the period			(4,219)	(6,303)

Comments on the operations and the results are set out below:

The Company's activities in the period under review continued to be focused on the registration, manufacturing, marketing and sales of biopharmaceutical products – namely Human Growth Hormone (Scitropin™), SciGen's 3rd generation Hepatitis B Vaccine (Sci-B-Vac™) and recombinant Human Insulin (SciLin™).

A new product, diabetic foot care cream (Pedimed™) was successfully registered in Australia and pre-marketing activities will commence in last quarter of 2010 during the Australian Diabetes Conference. Official launch of the product is forecast in January 2011.

During the six months ended and for the period to-date, registration of products were granted or achieved in the regions denoted by √ in the table below.

The Company achieved the following registrations as at the end of the period in the table below :

Country	**Scitropin™ (Sandoz)**	**Sci-B-Vac™ (SciGen Israel)**	**Sci-Locyte™ (INTAS)**	**SciLin™ (Bioton)**	**Pedimed (Pierre Fabre)**
Australia	Registered	–	–	–	√
China	–	–	–	Registered	–
Hong Kong	Registered	Registered	–	Registered	–
India	Registered	Registered	–	Registered	–
Indonesia	–	–	–	Registered	–
Israel	–	Registered	–	–	–
Korea	Registered	–	–	In progress	–
Malaysia	In progress	–	–	–	–
Myanmar	–	–	–	In progress	–
Pakistan	–	–	–	Registered	–
Philippines	Registered	Registered	Registered	Registered	–
Singapore	Registered	–	–	–	In progress
Thailand	In progress	–	–	Registered	–
Vietnam	√	In progress	–	Registered	–

ON BEHALF OF BOARD OF DIRECTORS

Slawomir Ziegert

....
Slawomir Ziegert
Chief Executive Officer & Director

....
Kenneth Gross
Non-Executive Director

Singapore
13 August 2010

SCIGEN LTD AND ITS SUBSIDIARIES

STATEMENT OF DIRECTORS

In the opinion of the directors,

(a) the unaudited condensed consolidated interim financial statements of the Group set out on pages 7 to 20 are drawn up so as to give a true and fair view of the state of affairs of the Group as at 30 June, 2010 and of the results, changes in equity and cash flows of the Group for the six-month period ended 30 June, 2010.

(b) at the date of this statement, having regard to the financial support provided by the holding company and that the holding company has confirmed that it will not demand for settlement of the loans given to the Company within the next twelve months, there are reasonable grounds to believe that the Group will be able to pay its debts as and when they fall due.

ON BEHALF OF BOARD OF DIRECTORS

Slawomir Ziegert

....
Slawomir Ziegert
Chief Executive Officer & Director

....
Kenneth Gross
Non-Executive Director

Singapore
13 August 2010

SCIGEN LTD AND ITS SUBSIDIARIES

INDEPENDENT AUDITORS' REVIEW REPORT ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The Board of Directors
SciGen Ltd
152 Beach Road
#26-07/08 Gateway East
Singapore 189721

Introduction

We have reviewed the accompanying condensed consolidated interim financial statements of SciGen Ltd (the "Company") and its subsidiaries (the "Group") which comprise the condensed consolidated interim statement of financial position of the Group as at 30 June, 2010, and the related condensed consolidated interim statements of comprehensive income, statement of changes in equity and statement of cash flows for the six-month period ended and certain explanatory notes as set out on pages 7 to 20.

The financial statements of the Company and the Group for the year ended 31 December, 2009 were audited by another auditor who expressed unmodified opinion on the financial statements in their report dated 30 March, 2010.

The unaudited condensed consolidated interim financial statements for the six-month ended 30 June, 2009, was reviewed by another auditor who have included emphasis of matter paragraphs relating to the going concern basis used to prepare the unaudited condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of this condensed consolidated interim financial statements in accordance with Singapore Financial Reporting Standard ("FRS") 34 *Interim Financial Reporting* ("FRS 34"). Our responsibility is to express a conclusion on this condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with Singapore Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of condensed consolidated interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Singapore Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with FRS 34.

This report has been prepared for the purpose of filing the condensed consolidated interim financial statements to the Australian Securities Exchange ("ASX"). This report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Deloitte & Touche LLP

Deloitte & Touche LLP
Public Accountants and
Certified Public Accountants

Singapore
13 August 2010

SCIGEN LTD AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION
As at 30 June, 2010

	Note	30 June, 2010 US$'000 **(Unaudited)**	31 December, 2009 US$'000 **(Audited)**
ASSETS			
Current assets			
Cash and cash equivalents		3,043	4,889
Trade and other receivables		4,485	3,915
Inventories		3,102	2,636
		10,630	11,440
Assets classified as held for sale		1,055	1,051
Total current assets		11,685	12,491
Non-current assets			
Property, plant and equipment	6	37,351	37,605
Intangible assets	7	20,534	20,508
Lease prepayment		357	362
Investment property	8	-	245
Deferred tax assets		12	12
Total non-current assets		58,254	58,732
Total assets		69,939	71,223
LIABILITIES AND EQUITY			
Current liabilities			
Trade and other payables		21,220	19,691
Current tax payable		71	55
Total current liabilities		21,291	19,746
Non-current liabilities			
Other payables		6,479	6,022
Bank loan		15	17
Loan from ultimate holding company	9	71,947	71,127
Total non-current liabilities		78,441	77,166
Capital, reserves and minority interest			
Share capital		42,530	42,530
Translation reserves		(952)	(1,051)
Accumulated losses		(75,442)	(71,388)
Capital deficiency		(33,864)	(29,909)
Minority interests		4,071	4,220
Total equity		(29,793)	(25,689)
Total liabilities and equity		69,939	71,223

See accompanying notes to financial statements.

SCIGEN LTD AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME
For the six-month period ended 30 June, 2010

	Note	Six months ended 30 June, 2010 US$'000 (Unaudited)	Six months ended 30 June, 2009 US$'000 (Unaudited)
Revenue		6,168	4,466
Other income (net)		747	143
Changes in inventories of finished goods		(193)	200
Purchases		(2,311)	(2,259)
Staff costs		(3,091)	(4,529)
Depreciation of property, plant and equipment		(862)	(33)
Depreciation of investment property		-	(16)
Amortisation of lease prepayment		(6)	(23)
Amortisation of intangible assets		(96)	(64)
Other operating expenses		(3,736)	(3,671)
Loss from operating activities		(3,380)	(5,786)
Finance income		29	307
Finance expense		(797)	(798)
Net finance expense	10	(768)	(491)
Loss from operating activities before income tax		(4,148)	(6,277)
Income tax expense		(71)	(26)
Loss for the period	10	(4,219)	(6,303)
Exchange differences on translating foreign operations, representing other comprehensive income for the period, net of tax		115	501
Total comprehensive losses for the period		(4,104)	(5,802)
Loss for the period attributable to:			
Equity holders of the Company		(4,054)	(6,245)
Minority interest		(165)	(58)
Loss for the period		(4,219)	(6,303)
Total comprehensive losses attributable to:			
Equity holders of the Company		(3,955)	(5,744)
Minority interest		(149)	(58)
Total comprehensive losses for the period		(4,104)	(5,802)
Loss per share			
Basic loss per share (cents)	11	(0.73)	(1.14)
Diluted loss per share (cents)	11	(0.73)	(1.14)

Note: There is no tax effect on the component indicated in the other comprehensive income.

See accompanying notes to financial statements.

SCIGEN LTD AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
For the six-month period ended 30 June, 2010

	Share capital US$'000	Translation reserves US$'000	Share option reserve US$'000	Accumulated losses US$'000	Attributable to equity holders of the Company US$'000	Minority interests US$'000	Total US$'000
At 1 January, 2009	42,530	(3,300)	1,600	(34,351)	6,479	5,808	12,287
Total comprehensive income/(loss) for the period	-	501	-	(6,245)	(5,744)	(58)	(5,802)
Contribution by minority shareholders of a subsidiary	-	-	-	-	-	130	130
Equity-settled share-based payment transactions	-	-	131	-	131	-	131
At 30 June, 2009	42,530	(2,799)	1,731	(40,596)	866	5,880	6,746
At 1 January, 2010	42,530	(1,051)	-	(71,388)	(29,909)	4,220	(25,689)
Total comprehensive income/(loss) for the period	-	99	-	(4,054)	(3,955)	(149)	(4,104)
At 30 June, 2010	42,530	(952)	-	(75,442)	(33,864)	4,071	29,793

See accompanying notes to financial statements.

SCIGEN LTD AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
For the six-month period ended 30 June, 2010

	30 June, 2010 US$'000 **(Unaudited)**	30 June, 2009 US$'000 **(Unaudited)**
Operating activities		
Loss before income tax	(4,148)	(6,277)
Adjustments for:		
Depreciation of property, plant and equipment	862	33
Depreciation of investment property	-	16
Amortisation of lease prepayment	5	23
Amortisation of intangible assets	96	64
Gain on disposal of investment property	(358)	-
Loss on disposal of property, plant and equipment	3	68
Intangible assets written-off	4	1,607
Equity-settled share-based payment transactions	-	131
Interest income	(29)	(237)
Interest expenses	797	798
Net foreign exchange losses	30	-
Operating cash flow before movement in working capital	(2,738)	(3,774)
Inventories	(466)	(769)
Trade and other receivables	(570)	3,248
Trade and other payables	1,306	31
Cash used in operations	(2,468)	(1,264)
Income taxes paid	-	(26)
Net cash flows used in operating activities	(2,468)	(1,290)
Investing activities		
Interest received	29	16
Purchase of property, plant and equipment	(655)	(2,855)
Purchase of intangible assets	(127)	(357)
Proceeds from disposal of property, plant and equipment	4	-
Proceeds from disposal of investment property	615	-
Net cash flows used in investing activities	(134)	(3,196)
Financing activities		
Interest paid	(117)	(12)
Proceeds from bank loan	-	9
Repayment of bank loan	(2)	-
Loans from holding company	820	3,706
Capital contribution by minority shareholders of a subsidiary	-	130
Net cash flows from financing activities	701	3,833
Net decrease in cash and cash equivalents	(1,901)	(653)
Cash and cash equivalents at beginning of the period	4,889	6,092
Effect of exchange rate fluctuations on cash held	55	(495)
Cash and cash equivalents at end of the period	3,043	4,944

See accompanying notes to financial statements.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
30 June, 2010

1 GENERAL

SciGen Ltd (the "Company") with Registration Number. 199805796R is incorporated in the Republic of Singapore and is a public limited company listed on Australian Stock Exchange.

The principal place of business and registered office is located at 152 Beach Road, #26-07/08 Gateway East, Singapore 189721. The condensed consolidated interim financial statements are presented in United Stated dollars, which is the Company's functional currency and rounded to the nearest thousand, unless stated otherwise.

The principal activities of the Group and of the Company are those relating to the manufacture and distribution of biopharmaceutical products under exclusive licensing arrangements.

As at 30 June 2010, the Group had a net loss of US$4,219,000 for the six-month period ended 30 June, 2010, and, as of that date, the Group had net current liabilities of US$9,606,000 and capital deficiency of US$33,864,000.

Management of the Company consider that it is appropriate for the Company to prepare its condensed consolidated interim financial statements on a going concern basis as the Company has received an undertaking from the holding company to continue to provide the Group with financial and other support as necessary for the next twelve months to enable the Group to continue as a going concern and to support their operating and investing activities for at least another twelve months since 31 December, 2009.

The holding company has also undertaken that it will not demand for settlement of the loans granted to the Company of US$78,426,000, which are due for repayment on 31 December, 2011.

The condensed consolidated interim financial statements of the Group for the six-month period ended 30 June, 2010 were authorised for issued by the Board of Directors on 13 August, 2010.

2 BASIC OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The unaudited condensed consolidated interim financial statements of SciGen Ltd and its subsidiaries have been prepared using accounting policies consistent with Singapore Financial Reporting Standards ("FRS") and in accordance with FRS 34 "*Interim Financial Reporting*".

The unaudited condensed consolidated interim financial statements, which do not include the full disclosures of the items normally included in a complete set of financial statements, are to be read in conjunction with the last issued audited financial statements as at 31 December, 2009.

The unaudited condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention, except for the revaluation of certain financial instruments.

Significant accounting policies

The significant accounting policies and methods of computation in the unaudited condensed consolidated interim financial statements are consistent with those applied in the Group's consolidated financial statements for the year ended 31 December, 2009, except that the Group has adopted all the new FRSs and Interpretation of FRS ("INT FRS") that are relevant to its operations and effective for annual period beginning 1 January, 2010. The adoption of these new/revised FRSs and INT FRS does not result in changes to the Group accounting policies and has no material effects on the amounts reported for the current or prior years financial statements.

On 1 January, 2010, the Group adopted the following new or revised FRS and INT FRS that are issued by the Accounting Standard Council (ASC), and are relevant for the Group.

- FRS 27 Consolidated and Separate Financial Statements
- FRS 103 Business Combinations
- FRS 39 (Amendments) Financial Instruments: Recognition and Measurement
  - Eligible Hedged Items
  - Embedded Derivatives
- FRS 102 (Amendments) Share-Based Payment – Group Cash-settled Share-based Payment Transactions
- INT FRS 109 (Amendments) Reassessment of Embedded Derivatives
- INT FRS 117 Distributions of Non-cash Assets to Owners
- Improvements to FRSs

ADOPTION OF NEW OR REVISED FRS AND INT FRS

FRS 27*: Consolidated and Separate Financial Statements*

The standard requires the effects of all transactions with non-controlling interests to be recorded in equity if there is no change in control. Such transactions will have no impact on goodwill, nor will it give rise to a gain or loss. The standard also specifies the accounting when control is lost. Any remaining interest in the entity is re-measured to fair value, and a gain or loss is recognised in profit or loss.

The changes introduced by FRS 27 must be applied prospectively and will affect future transactions with non-controlling interests.

FRS 103: Business Combinations

The revised FRS 103 becomes effective for financial years beginning on or after 1 January, 2010. It introduces a number of changes in the accounting for business combinations. For example, there is a choice on an acquisition-by-acquisition basis to measure the non-controlling interest in the acquiree either at fair value or at the non-controlling interest's proportionate share of the acquiree's net assets. All acquisition-related costs should be expensed.

The changes introduced by FRS 103 must be applied prospectively and will affect future business combinations.

There is no expected material impact of the Group's financial statements from the adoption of all the other new or revised FRS and INT FRS above.

3 HOLDING COMPANY AND RELATED COMPANY TRANSACTIONS

The Company is a subsidiary of Bioton S.A., incorporated in Poland. Related companies refer to members of the holding company's Group of companies.

Transactions between subsidiaries have been eliminated on consolidation. Transactions with the ultimate holding company during the period are disclosed in Note 4 below.

4 OTHER RELATED PARTY TRANSACTIONS

Related parties are entities with common direct or indirect shareholders and/or directors. Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions.

Some of the Company's transactions and arrangements are with related parties and the effect of these on the basis determined between the parties are reflected in these condensed consolidated interim financial statements.

The following transactions took place between the Group and related parties (related by way of common directors) during the period:

	30 June, 2010 US$'000 **(Unaudited)**	30 June, 2009 US$'000 **(Unaudited)**
Holding company		
Purchases of goods	1,206	1,261

Compensation of directors and key management personnel

Remuneration and retirement benefits paid/payable to directors are as follows:

	30 June, 2010 US$'000 **(Unaudited)**	30 June, 2009 US$'000 **(Unaudited)**
Income paid or payable, or otherwise made available, to directors by the entities in the Group and the Company	400	1,025
Termination benefits payable to an ex-director of the Company	-	2,600
	400	3,625

The remuneration and retirement benefits paid/payable to directors for period ended 30 June, 2009 include the termination benefits of US$2.6 million payable to an ex-director of the Company whose appointment was terminated on 29 June, 2009.

5 SEASONAL OPERATIONS

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

6 PROPERTY, PLANT AND EQUIPMENT

During the six-month period ended 30 June, 2010, the Group acquired property, plant and equipment and capitalised construction cost of approximately US$306,000 and US$349,000 (31 December, 2009: US$772,000 and US$7,663,000) respectively.

It also disposed certain of its property, plant and equipment with carrying amount of US$7,000 for proceed of US$4,000 (31 December, 2009: NIL).

7 INTANGIBLE ASSETS

During the six-month period ended 30 June, 2010, the Group acquired intangible assets of approximately US$127,000 (31 December, 2009: US$1,284,000) and written off intangible assets amounting to US$4,000 (31 December, 2009: US$3,479,000).

8 INVESTMENT PROPERTY

During the six-month period ended 30 June, 2010, the Group disposed investment property with carrying amount of US$257,000 for proceed of US$615,000 (31 December, 2009: NIL).

9 LOAN FROM ULTIMATE HOLDING COMPANY

The loans from holding company bear interest of LIBOR 3 months + 1% (31 December, 2009 : LIBOR 3 months + 1%) per annum. The loans and interest payable are due for repayment on 31 December, 2011. The effective interest rate for the loan is 1.39% (31 December, 2009 : 1.76%) per annum.

10 LOSS FOR THE PERIOD

	30 June, 2010 US$'000 **(Unaudited)**	30 June, 2009 US$'000 **(Unaudited)**
Share-based payment, included in staff costs	-	131
Loss on disposal of property, plant and equipment	3	68
Gain on disposal of investment property	(358)	-
Intangible assets written-off	-	1,607
Finance income:		
Interest received from banks	(29)	(16)
Deemed interest income on non-current payables	-	(221)
	(29)	(237)
Exchange gain	-	(70)
	(29)	(307)
Finance expense:		
Interest expense paid to banks/others	117	12
Interest expense payable to holding company	517	786
	634	798
Exchange loss	163	-
	797	798

11 LOSS PER SHARE

	30 June, 2010 US$'000 **(Unaudited)**	30 June, 2009 US$'000 **(Unaudited)**
Basic and diluted loss per share is based on:		
(i) Net loss attributable to equity holders of the company	(4,054)	(6,245)

	30 June, 2010 Number of ordinary shares '000	30 June, 2009 Number of ordinary shares '000
(ii) Weighted average number of ordinary shares at the end of the period	552,270	552,270

For the financial period ended 30 June, 2009, the option granted to an ex-director was no included in the determination of diluted loss per share of the Group, as the option are considered to be anti-dilutive potential ordinary shares.

12 SEGMENT INFORMATION

Segment information is presented in respect of the Group's geographical segments. The reportable segment presentation is based on the Group's management and internal reporting structure, used for its strategic decision-making purposes. Intersegment pricing is determined on mutually agreed terms.

Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly investments (other than the investment property) and related revenue, loans and expenses, corporate assets and head office expenses.

Segment capital expenditure is the total cost incurred during the year to acquire property, plant and equipment, and intangible assets other than goodwill.

The Group's reportable segments are as follows:

Singapore
The home country of the parent entity which is also the main operating entity. The areas of operation are principally corporate office functions and sales and marketing.

Australia
Includes sales and marketing activities.

India
Includes sales and marketing and manufacturing activities.

Korea
Includes sales and marketing activities.

Thailand
Includes sales and marketing activities.

Israel
Includes sales and marketing and manufacturing activities.

Vietnam
Includes sales and marketing activities.

Philippines
Includes sales and marketing activities.

China
Includes sales and marketing and manufacturing activities.

Others
Comprises operations carried on in Indonesia and Pakistan. None of these segments meets any of the quantitative thresholds for determining reportable segments in 2010 or 2009.

Major customers
Revenue from two customers, namely from Vietnam and Thailand, represent approximately US$2,505,000 (June 2009 : US$1,730,000 from India and Thailand) of the Company's total revenue.

Information regarding the Group's reportable segments is presented below.

For the six-month period ended 30 June, 2010	Singapore US$'000 (Unaudited)	Australia US$'000 (Unaudited)	India US$'000 (Unaudited)	Korea US$'000 (Unaudited)	Thailand US$'000 (Unaudited)	Israel US$'000 (Unaudited)	Vietnam US$'000 (Unaudited)	Philippines US$'000 (Unaudited)	China US$'000 (Unaudited)	Others US$'000 (Unaudited)	Eliminations US$'000 (Unaudited)	Total US$'000 (Unaudited)
Revenue												
Sales to external customers	-	2,202	-	711	823	50	1,682	653	-	47	-	6,168
Inter-segment sales	909	-	-	-	-	-	-	-	-	-	(909)	-
Total sales revenue	909	2,202	-	711	823	-	-	-	-	2,432	(909)	6,168
Results												
Segment results	(15)	511	(304)	(78)	111	(2,251)	284	112	(336)	13	-	(1,953)
Unallocated revenue less unallocated expenses												(2,195)
Loss from operating activities before income tax												(4,148)
Income tax expense												(71)
Loss for the period												(4,219)
Other segment information												
Depreciation and amortisation	-	16	107	3	-	664	-	-	81	-	-	871
Unallocated depreciation and amortisation												93
Total depreciation and amortisation												964
Additions to intangible assets and property, plant and equipment	-	17	113	5	-	116	-	-	464	-	-	715
Unallocated additions to intangible assets and property, plant and equipment												67
Total additions to intangible assets and property, plant and equipment												782
Intangible asset written-off	-	-	4	-	-	-	-	-	-	-	-	4

As at 30 June, 2010	Singapore US$'000 (Unaudited)	Australia US$'000 (Unaudited)	India US$'000 (Unaudited)	Korea US$'000 (Unaudited)	Thailand US$'000 (Unaudited)	Israel US$'000 (Unaudited)	Vietnam US$'000 (Unaudited)	Philippines US$'000 (Unaudited)	China US$'000 (Unaudited)	Others US$'000 (Unaudited)	Eliminations US$'000 (Unaudited)	Total US$'000 (Unaudited)
Segment Assets												
Total non-current assets	-	93	18,730	22	-	10,392	-	3	8,276	-	-	37,516
Deferred tax assets	-	-	-	-	-	12	-	-	-	-	-	12
Total current assets	-	1,726	3,036	563	162	2,513	484	408	1,874	-	-	10,766
Segment assets	-	1,819	21,766	585	162	12,917	484	411	10,150	-	-	48,294
Unallocated assets												21,645
Total assets												69,939
Segment liabilities												
Segment liabilities	-	(125)	(3,230)	(109)	(21)	(717)	(244)	(63)	(1,643)	-	-	(6,152)
Unallocated liabilities												(93,580)
Total liabilities												(99,732)

For the six-month period ended 30 June, 2009	Singapore US$'000 **(Unaudited)**	Australia US$'000 **(Unaudited)**	India US$'000 **(Unaudited)**	Korea US$'000 **(Unaudited)**	Thailand US$'000 **(Unaudited)**	Israel US$'000 **(Unaudited)**	Vietnam US$'000 **(Unaudited)**	Philippines US$'000 **(Unaudited)**	China US$'000 **(Unaudited)**	Others US$'000 **(Unaudited)**	Eliminations US$'000 **(Unaudited)**	Total US$'000 **(Unaudited)**
Revenue												
Sales to external customers	-	1,660	954	610	776	-	-	466	-	-	-	4,466
Inter-segment sales	706	-	-	-	-	-	-	-	-	-	(706)	-
Total sales revenue	706	1,660	954	610	776	-	-	466	-	-	(706)	4,466
Results												
Segment results	596	(511)	104	(52)	98	(63)	(16)	12	(117)	101	-	152
Unallocated revenue less unallocated expenses												(6,429)
Loss from operating activities before income tax												(6,277)
Income tax expense												(26)
Loss for the period												(6,303)
Other segment information												
Depreciation and amortisation	-	10	16	1	-	-	-	-	23	-	-	50
Unallocated depreciation and amortisation												86
Total depreciation and amortisation												136
Additions to intangible assets and property, plant and equipment	-	21	1,819	-	-	-	-	-	-	-	-	1,840
Unallocated additions to intangible assets and property, plant and equipment												2,893
Total additions to intangible assets and property, plant and equipment												4,733
Intangible asset written-off	1,607	-	-	-	-	-	-	-	-	-	-	1,607

As at 31 December, 2009	Singapore US$'000 **(Audited)**	Australia US$'000 **(Audited)**	India US$'000 **(Audited)**	Korea US$'000 **(Audited)**	Thailand US$'000 **(Audited)**	Israel US$'000 **(Audited)**	Vietnam US$'000 **(Audited)**	Philippines US$'000 **(Audited)**	China US$'000 **(Audited)**	Others US$'000 **(Audited)**	Eliminations US$'000 **(Audited)**	Total US$'000 **(Audited)**
Segment Assets												
Total non-current assets	-	96	18,619	21	-	11,103	-	3	8,218	-	-	38,060
Deferred tax assets	-	-	-	-	-	12	-	-	-	-	-	12
Total current assets	-	2,070	2,796	464	174	2,660	463	429	2,057	75	-	11,188
Segment assets	-	2,166	21,415	485	174	13,775	463	432	10,275	75	-	49,260
Unallocated assets												21,963
Total assets												71,223
Segment liabilities												
Segment liabilities	-	(124)	(3,160)	(80)	(23)	(793)	(362)	(50)	(1,512)	-	-	(6,104)
Unallocated liabilities												(90,807)
Total liabilities												(96,911)

13 COMMITMENTS

Commitments not reflected in the unaudited condensed consolidated interim financial statements at the reporting dates are as follows:

(a) Operating lease commitments

At 30 June, 2010, the Group has commitments for future minimum lease payments under non-cancellable operating leases are as follows:

	30 June, 2010 US$'000 **(Unaudited)**	31 December, 2009 US$'000 **(Audited)**
Within 1 year	553	575
After 1 year but within 5 years	570	235
	1,123	810

The Group leases out its investment property. Operating lease rentals are receivable as follows:

	30 June, 2010 US$'000 **(Unaudited)**	31 December, 2009 US$'000 **(Audited)**
Within 1 year	-	3
After 1 year but within 5 years	-	-
	-	3

(b) Capital commitments

	30 June, 2010 US$'000 **(Unaudited)**	31 December, 2009 US$'000 **(Audited)**
Capital expenditure contracted but not provided for in the condensed consolidated interim financial statements is as follows:		
Acquisition of assets	6,200	6,200

14 RECLASSIFICATIONS

Certain reclassifications have been made to the prior year's financial statements to reclass construction work-in-progress amounting to US$250,000 which was previously included in other receivables to property, plant and equipment. As the construction work-in-progress is not subjected to depreciation, there is no restatement required for statement of comprehensive income.

As a result, certain line items have been amended in the condensed consolidated interim statement of financial position and related notes to financial statements.

The items were reclassified as follows:

	Previously reported	After, reclassification
	US$'000	US$'000
Property, plant and equipment	37,355	37,605
Trade and other receivables	4,165	3,915

SCIGEN LTD AND ITS SUBSIDIARIES

SUPPLEMENTARY APPENDIX 4D INFORMATION

NTA backing

	30 June, 2010 (cents)	31 December, 2009 (cents)
Net liabilities backing per ordinary share	(5.39)	(4.65)

Controlled entities acquired or disposed of

Acquired			
Date control gained	N/A	N/A	N/A
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A

Disposed of			
Date control lost	N/A	N/A	N/A
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A

Additional dividend/distributions information

There are no dividends or distributions declared or paid during or subsequent to the six-month period ended 30 June, 2010.

Dividend/distribution reinvestment plans

There are no dividends or distribution reinvestment plans during or subsequent to the six-month period ended 30 June, 2010.

Associates and Joint Venture entities

There are no investments in associates or joint venture entities during the as at 30 June, 2010 or subsequent to the six-month period ended 30 June, 2010.

Foreign Accounting Standards

This six-month period ended report for the interim reporting period ended 30 June, 2010 has been prepared in accordance with Singapore Financial Reporting Standards.

SCIGEN LTD AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

C O N T E N T S

GRP1-MGR/3019054-4007611-FS/NPH/AMCM/WOWS/JKLC

SCIGEN LTD AND ITS SUBSIDIARIES
(Registration No. 199805796R)

INDEPENDENT AUDITORS' REVIEW REPORT AND CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE SIX-MONTH PERIOD ENDED 30 JUNE, 2010